A novel rat full‐thickness hemi‐abdominal wall/hindlimb osteomyocutaneous combined flap: influence of allograft mass and vascularized bone marrow content on vascularized composite allograft survival. (29th July 2014)

• Record Type: Journal Article
• Authors: Ramirez, Alejandro E.; Cheng, Hui‐Yun; Lao, William W.; Wang, Yen‐Ling; Wen, Chih‐Jen; Wallace, Christopher G.; Lin, Chih‐Fan; Shih, Ling‐Yi; Chuang, Sheng‐Hao; Wei, Fu‐Chan
• Is Part Of: Transplant international. Volume 27:Number 9(2014:Sep.)
• Page Start: 977
• Page End: 986
• Publication Date: 2014-07-29
• Subjects: Transplantation of organs, tissues, etc -- Periodicals; 617.95405
• DOI: 10.1111/tri.12364
• Languages: English
• ISSNs: 0934-0874

Abstract

<abstract abstract-type="main" id="tri12364-abs-0001"> <title>Abstract</title> <p>Vascularized bone marrow transplantation (VBMT) appears to promote tolerance for vascularized composite allotransplantation (VCA). However, it is unclear whether VBMT is critical for tolerance induction and, if so, whether there is a finite amount of VCA that VBMT can support. We investigated this with a novel VCA combined flap model incorporating full‐thickness hemiabdominal wall and hindlimb osteomyocutaneous (HAW/HLOMC) flaps. Effects of allograft mass (AM) and VBMT on VCA outcome were studied by comparing HAW/HLOMC VCAs with fully MHC‐mismatched BN donors and Lewis recipients. Control groups did not receive treatments following transplantation. Treatment groups received a short course of cyclosporine A (CsA), antilymphocyte serum, and three doses of adipocyte‐derived stem cells (POD 1, 8, and 15). The results showed that all flaps in control allogeneic groups rejected soon after VCAs. Treatment significantly prolonged allograft survival. Three of eight recipients in HLOMC treatment group had allografts survive long‐term and developed donor‐specific tolerance. Significantly higher peripheral chimerism was observed in HLOMC than other groups. It is concluded that the relative amount of AM to VBMT is a critical factor influencing long‐term allograft survival. Accordingly, VBMT content compared with VCA mass may be an important consideration for VCA in humans.</p> </abstract>